Second Sight Medical Products Company Profile (NASDAQ:EYES)

About Second Sight Medical Products (EYES)

Second Sight Medical Products logoSecond Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EYES
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $1.24
  • 50 Day Moving Average: $1.59
  • 200 Day Moving Average: $2.20
  • 52-Week Range: $1.06 - $6.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.34
  • P/E Growth: 0.00
  • Market Cap: $69.89M
  • Outstanding Shares: 42,424,000
  • Beta: 3.44
Profitability:
  • Net Margins: -502.22%
  • Return on Equity: -121.31%
  • Return on Assets: -92.60%
Debt:
  • Current Ratio: 4.36%
  • Quick Ratio: 3.33%

Analyst Ratings

Consensus Ratings for Second Sight Medical Products (NASDAQ:EYES) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (1,190.32% upside)

Analysts' Ratings History for Second Sight Medical Products (NASDAQ:EYES)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/25/2016HC WainwrightSet Price TargetBuy$16.00N/AView Rating Details
7/26/2016Rodman & RenshawReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 3/25/2015 forward)

Earnings

Earnings History for Second Sight Medical Products (NASDAQ:EYES)
Earnings by Quarter for Second Sight Medical Products (NASDAQ:EYES)
Earnings History by Quarter for Second Sight Medical Products (NASDAQ:EYES)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
3/9/2017Q4 2016($0.17)($0.24)$1.76 million$0.72 millionViewListenView Earnings Details
11/2/2016Q316($0.16)($0.15)$2.36 million$1.20 millionViewN/AView Earnings Details
7/28/2016Q216($0.15)($0.17)$2.66 million$1.04 millionViewListenView Earnings Details
4/28/2016Q116($0.16)($0.13)$1.38 million$1.05 millionViewListenView Earnings Details
3/3/2016Q415($0.14)($0.13)$2.47 million$2.40 millionViewN/AView Earnings Details
10/29/2015Q315($0.14)($0.13)$2.05 million$2.23 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.73 million$2.70 millionViewN/AView Earnings Details
5/13/2015Q115($0.12)$1.70 millionViewListenView Earnings Details
3/11/2015Q414($0.17)$1.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Second Sight Medical Products (NASDAQ:EYES)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.53 EPS

Dividends

Dividend History for Second Sight Medical Products (NASDAQ:EYES)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Second Sight Medical Products (NASDAQ:EYES)
Insider Ownership Percentage: 34.70%
Institutional Ownership Percentage: 6.57%
Insider Trades by Quarter for Second Sight Medical Products (NASDAQ:EYES)
Institutional Ownership by Quarter for Second Sight Medical Products (NASDAQ:EYES)
Insider Trades by Quarter for Second Sight Medical Products (NASDAQ:EYES)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2016Robert J GreenbergChairmanSell1,950$1.96$3,822.00View SEC Filing  
6/3/2016Edward David RandolphVPSell5,104$4.01$20,467.04View SEC Filing  
6/2/2016Robert J GreenbergChairmanSell8,571$4.10$35,141.10View SEC Filing  
4/18/2016Robert J GreenbergChairmanSell8,223$5.27$43,335.21View SEC Filing  
12/7/2015Robert J. GreenbergChairmanSell17,969$5.30$95,235.70View SEC Filing  
12/4/2015Anne-Marie Juliette RipleyVPSell2,500$5.50$13,750.00View SEC Filing  
6/4/2015Anne-Marie Juliette RipleyVPSell4,371$15.00$65,565.00View SEC Filing  
6/3/2015Robert J GreenbergCEOSell150,000$14.04$2,106,000.00View SEC Filing  
5/27/2015Anne-Marie Juliette RipleyVPSell45,629$13.04$595,002.16View SEC Filing  
3/23/2015Robert J GreenbergCEOSell100,000$13.28$1,328,000.00View SEC Filing  
11/19/2014Gregg WilliamsDirectorBuy111,111$9.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Second Sight Medical Products (NASDAQ:EYES)
Latest Headlines for Second Sight Medical Products (NASDAQ:EYES)
Source:
DateHeadline
finance.yahoo.com logoSECOND SIGHT MEDICAL PRODUCTS INC Financials
finance.yahoo.com - March 21 at 5:19 PM
biz.yahoo.com logoSECOND SIGHT MEDICAL PRODUCTS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 6:28 PM
biz.yahoo.com logoSECOND SIGHT MEDICAL PRODUCTS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Di
biz.yahoo.com - March 15 at 7:43 AM
seekingalpha.com logoSecond Sight Medical Products' (EYES) CEO Will McGuire on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 10 at 11:18 AM
us.rd.yahoo.com logoSecond Sight Medical Products, Inc. Announces Completion of Oversubscribed Rights Offering
us.rd.yahoo.com - March 9 at 5:37 PM
biz.yahoo.com logoQ4 2016 Second Sight Medical Products Inc Earnings Release - After Market Close
us.rd.yahoo.com - March 9 at 5:37 PM
us.rd.yahoo.com logoSecond Sight Reports Fourth Quarter and Year End 2016 Financial Results
us.rd.yahoo.com - March 9 at 5:37 PM
americanbankingnews.com logoSecond Sight Medical Products Inc (EYES) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - March 9 at 5:06 PM
biz.yahoo.com logoSECOND SIGHT MEDICAL PRODUCTS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - March 7 at 11:40 AM
finance.yahoo.com logoSecond Sight Appoints David Jacques as Vice President of Research and Development
finance.yahoo.com - March 2 at 9:02 AM
finance.yahoo.com logoSecond Sight to Discuss Fourth Quarter and Year-End 2016 Financial Results on March 9, 2017 Conference Call
finance.yahoo.com - March 1 at 4:50 PM
biz.yahoo.com logoSECOND SIGHT MEDICAL PRODUCTS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 27 at 7:21 PM
businesswire.com logoSecond Sight Announces Professor Stanislao Rizzo Has Completed His 30 - Business Wire (press release)
www.businesswire.com - February 23 at 5:07 PM
finance.yahoo.com logoSecond Sight Announces Professor Stanislao Rizzo Has Completed His 30th Implant of the Argus II Retinal Prosthesis
finance.yahoo.com - February 22 at 9:11 AM
prnewswire.com logoSight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts
www.prnewswire.com - February 16 at 5:04 PM
businesswire.com logoSecond Sight Medical Products, Inc. Announces Record Date ... - Business Wire (press release)
www.businesswire.com - February 6 at 5:09 PM
finance.yahoo.com logoSecond Sight Medical Products, Inc. Announces Record Date, Subscription Pricing, Expiration Date for Rights Offering and Effectiveness of Its Registration Statement
finance.yahoo.com - February 6 at 11:06 AM
finance.yahoo.com logoBlog Coverage Second Sight Wins Reimbursement Approval for Argus II Retinal Prosthesis System
finance.yahoo.com - February 3 at 5:31 PM
streetinsider.com logoSecond Sight Medical (EYES) Announces Positive Reimbursement Renewal Decision for Argus II in Germany
www.streetinsider.com - February 2 at 10:42 PM
uk.finance.yahoo.com logoSecond Sight Announces Positive Reimbursement Renewal Decision in Germany
us.rd.yahoo.com - February 2 at 10:42 PM
us.rd.yahoo.com logo8:03 am Second Sight Medical Products announces that the German Institute for the Hospital Remuneration System has renewed Status 1 (full approval) for the Epiretinal Prosthesis across 15 hospitals under the NUB1 innovation program
us.rd.yahoo.com - February 2 at 10:42 PM
streetinsider.com logoSecond Sight Medical (EYES) Announces Positive Reimbursement Renewal Decision for Argus II in Germany - StreetInsider.com
www.streetinsider.com - February 2 at 5:40 PM
finance.yahoo.com logoSecond Sight Medical Products, Inc. Announces Rights Offering
finance.yahoo.com - January 9 at 5:55 PM

Social

Frequently Asked Questions for Second Sight Medical Products (NASDAQ:EYES)

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) announced its earnings results on Thursday, March, 9th. The company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.07. The firm earned $0.72 million during the quarter, compared to analysts' expectations of $1.76 million. Second Sight Medical Products had a negative net margin of 502.22% and a negative return on equity of 121.31%. The business's revenue for the quarter was down 70.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.13) EPS.

When will Second Sight Medical Products make its next earnings announcement?

Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

Where is Second Sight Medical Products' stock going? Where will Second Sight Medical Products' stock price be in 2017?

2 analysts have issued 12-month price targets for Second Sight Medical Products' stock. Their forecasts range from $16.00 to $16.00. On average, they anticipate Second Sight Medical Products' stock price to reach $16.00 in the next year.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 4,607,675 shares, an increase of 39.7% from the January 31st total of 3,298,978 shares. Based on an average trading volume of 1,729,725 shares, the days-to-cover ratio is presently 2.7 days. Currently, 25.2% of the company's shares are short sold.

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Who owns Second Sight Medical Products stock?

Second Sight Medical Products' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.50%), Van Den Berg Management I Inc. (0.45%) and Psagot Investment House Ltd. (0.25%). Company insiders that own Second Sight Medical Products stock include Anne-Marie Juliette Ripley, Edward David Randolph and Robert J Greenberg.

Who sold Second Sight Medical Products stock? Who is selling Second Sight Medical Products stock?

Second Sight Medical Products' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have sold Second Sight Medical Products stock in the last year include Edward David Randolph and Robert J Greenberg.

Who bought Second Sight Medical Products stock? Who is buying Second Sight Medical Products stock?

Second Sight Medical Products' stock was acquired by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd. and Van Den Berg Management I Inc..

How do I buy Second Sight Medical Products stock?

Shares of Second Sight Medical Products can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Second Sight Medical Products stock cost?

One share of Second Sight Medical Products stock can currently be purchased for approximately $1.24.

Second Sight Medical Products (EYES) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by MarketBeat.com Staff